Novo Nordisk ousts CEO after falling behind in weight loss market

Status
Not open for further replies.
quoted said:
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from U.S. rival Eli Lilly (LLY.N) , makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.

On the surface, it does seem like Novo Nordisk is afraid to compete on price with Zepbound, even though doctors are recommending Zepbound over Wegovy.
 
Morbius said:
Everyone is dying for these meds, I am surprised the manufacturers don't just start their own telehealth services.
It costs almost nothing for the manufacturer to make. If they just were not as greedy as they are, and took this or a similar approach, they would have so many more patients. Patients=$
 
Status
Not open for further replies.

Trending content

Members online

No members online now.

Forum statistics

Threads
2,620
Messages
55,146
Members
1
Latest member
Admin
Back
Top